Teng Wei, Liu Yen-Chun, Jeng Wen-Juei, Su Chien-Wei
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, Taiwan.
College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan.
Cancers (Basel). 2021 Apr 6;13(7):1729. doi: 10.3390/cancers13071729.
Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility of curative treatment. However, high HCC recurrence rate still accounts for the poor prognosis of HCC patients. In this article, we critically review the pathogenesis of viral hepatitis-related hepatocellular carcinoma and the evidence of tertiary prevention efficacy by current available antiviral treatment, and discuss the knowledge gap in viral hepatitis-related HCC tertiary prevention.
肝细胞癌（HCC）是常见癌症及癌症相关死亡的主要原因之一。HCC的主要病因是慢性肝炎病毒感染，包括HBV和HCV感染。对高危人群进行定期的HCC监测可提高早期检测率及根治性治疗的可行性。然而，HCC的高复发率仍然是导致HCC患者预后不良的原因。在本文中，我们批判性地回顾了病毒性肝炎相关肝细胞癌的发病机制以及当前可用抗病毒治疗的三级预防疗效证据，并讨论了病毒性肝炎相关HCC三级预防中的知识空白。
